Pharmafile Logo
Pharmafocus logo
Advanced Search

arthritis

Showing 15 posts of 27 posts found.

180921-drugs-pills-bottle-faeture-image

Celltrion launches Humira biosimilar in US

July 7, 2023
Medical Communications Chronic Diseases, Humira, Yuflyma, arthritis, celltrion

South Korean biopharmaceutical company Celltrion has announced that its US branch – Celltrion USA – has launched a Humira (adalimumab) …

News

NICE recommends Janssen’s active psoriatic arthritis drug

May 28, 2021
Medical Communications Janssen, NICE, UK, arthritis

NICE have released a Final Appraisal Document (FAD) recommending Janssen’s tremfya (guselkumab) as a new option for treating active psoriatic …

News
NHS building

Abbvie psoriatic arthritis drug approved for use in Scotland

May 11, 2021
Manufacturing and Production AbbVie, NHS, arthritis, psoriatic arthritis

Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has been approved for use in …

News
Janssen sign

Johnson & Johnson’s arthritis drug shows promising results in Phase III trial

March 16, 2021
Manufacturing and Production Janssen, Johnson & Johnson, PSA, Tremfya, arthritis

Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.

News
Eli Lilly front sign

University of Glasgow and Lilly sign £4.6m immunological disease partnership

February 15, 2021
Sales and Marketing Eli Lilly, University of Glasgow, arthritis, fibrosis, lilly, uofg

The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, across four diseases, worth £4.6 …

News
european_commission_web

Jyseleca secures European approval in rheumatoid arthritis

September 28, 2020
Research and Development, Sales and Marketing Europe, Jyseleca, arthritis, pharma

The European Commission has awarded approval to Gilead and Galpagos for their oral JAK inhibitor Jyseleca (filgotinib) as a treatment …

News
abbvie_0

AbbVie granted EU marketing authorisation for new arthritis drug

December 19, 2019
Business Services AbbVie, EC, EU, arthritis, rheumatoid arthritis

AbbVie have announced that the European Commission (EC) have granted marketing authorisation for RINVOQ (upadacitnib). It’s a daily selective reversible …

News
celltrion1

Europe approves first subcutaneous version of biosimilar infliximab

November 26, 2019
Manufacturing and Production, Sales and Marketing arthritis, biosimilars, celltrion, infliximab, pharma

The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation …

News

Eli Lilly’s Taltz shows superiority over AbbVie’s Humira

December 18, 2018
Manufacturing and Production Eli Lilly, Humira, Taltz, arthritis, immune system

A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

April 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, FDA, Fresenius, Shire, Takeda, arthritis, pharma

The year seems like it’s running away as we come to the end of April. It’s been a more tense …

News
lilly_entrance_web

Lilly dumps Hanmi’s rheumatoid arthritis med

February 20, 2018
Manufacturing and Production, Sales and Marketing Eli Lilly, arthritis, hanmi, pharma

Eli Lilly and Hanmi signed an exclusive licensing and collaboration agreement to develop the Bruton’s tyrosine kinase (BTK) inhibitor, HM71224, …

News
lilly2_web

Lilly gets second shot at application for ‘blockbuster’ arthritis drug

August 31, 2017
Sales and Marketing Eli Lilly, arthritis, baricitinib, biotech, drugs, pharma, pharmaceutical

Earlier this year, Eli Lilly was on the receiving end of one of the most surprising setbacks in recent times …

News
blood-75301_640

Existing arthritis drug could save thousands in blood cancer treatment

August 3, 2017
Research and Development University of Sheffield, arthritis, biotech, blood cancer, drugs, life sciences, medicine, pharma, pharmaceutical

Findings by researchers at the University of Sheffield have indicated that thousands of pounds could be saved in blood cancer …

News

Sanofi and Regeneron score FDA approval for arthritis

May 23, 2017
Manufacturing and Production, Sales and Marketing FDA, Kevzara, arthritis, sarilumab

The FDA has awarded Sanofi and Regeneron’s Kevzara (sarilumab) approval for the treatment of moderate to severely active rheumatoid arthritis …

News

Roche says Phase III trials for giant cell arteritis drug met primary endpoint

June 6, 2016
Research and Development, Sales and Marketing Roche, arthritis, drug trial

Cancer drugmaker Roche (SIX: ROG) said late stage trials for its drug to treat giant cell arteritis (GCA) met its …

News

Latest content

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024